A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis
Status:
Completed
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR)
gamma. The aim of this study is to evaluate the safety, tolerability, clinical effect, and
systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque
psoriasis by treating all plaques on the body for 8 weeks. This single-center study will be
conducted in two parts. Part A will be an open-label, single arm study and part B will be a
double-blind, randomized, 2-arm, parallel-group, vehicle-controlled study. In Part A, 8 adult
subjects and in Part B, 18 adult subjects with chronic stable plaque psoriasis will be
enrolled. Total duration of study will be approximately 14 weeks. The results of this study
will provide preliminary information about safety and efficacy of the drug and will help in
providing the guidance for further development strategy.